Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Portola Pharmaceuticals Inc    PTLA

PORTOLA PHARMACEUTICALS INC (PTLA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
32.67(c) 33.71(c) 33.35(c) 32.98(c) 33.25(c) Last
495 605 935 951 595 697 834 994 855 552 Volume
+1.05% +3.18% -1.07% -1.11% +0.82% Change
More quotes
Financials (USD)
Sales 2018 90,6 M
EBIT 2018 -310 M
Net income 2018 -310 M
Finance 2018 80,4 M
Yield 2018 -
Sales 2019 328 M
EBIT 2019 -51,9 M
Net income 2019 -60,3 M
Finance 2019 113 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 23,1x
EV / Sales2019 6,29x
Capitalization 2 174 M
More Financials
Company
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders, and inflammation.Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of... 
More about the company
Surperformance© ratings of Portola Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PORTOLA PHARMACEUTICALS IN
04/06PORTOLA PHARMACEUTICALS : Reports Inducement Grants Under NASDAQ Listing Rule 56..
AQ
04/05PORTOLA PHARMACEUTICALS : Reports Inducement Grants Under NASDAQ Listing Rule 56..
AQ
04/04Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5..
GL
03/28PORTOLA PHARMACEUTICALS : Receives and Plans to Appeal Negative CHMP Opinion Reg..
AQ
03/23Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Re..
GL
03/16PORTOLA PHARMACEUTICALS : Appoints Biotech Legal Veteran John Moriarty as Execut..
AQ
03/16PORTOLA PHARMACEUTICALS : Announces New Interim Results from Ongoing ANNEXA-4 St..
AQ
03/15PORTOLA PHARMACEUTICALS : Pharmaceutical`s AndexXa Approval Remains Uncertain
AQ
03/13MANAGEMENT TRACKS : WuXi NextCode, Assembly
AQ
03/13PORTOLA PHARMACEUTICALS : Announces New Interim Results from Ongoing ANNEXA-4 St..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
04/20Somewhat Positive Press Coverage Somewhat Unlikely to Impact Portola Pharmace.. 
04/19William Blair Comments on Portola Pharmaceuticals’ FY2020 Earnings $PTLA  
04/19Brokers Set Expectations for Portola Pharmaceuticals’ Q1 2018 Earnings $PTLA .. 
04/18$NSPX HUGE Merger! NO PR $RDUS $UTHR $PTLA $ALDR $OPK $GLPG $ARWR $ONCS $MT.. 
04/18William Blair Lowers Portola Pharmaceuticals Q1 2018 Earnings Estimates to ($.. 
More tweets
Qtime:61
News from SeekingAlpha
03/27NHF : Objects In The Rear View Mirror Miss The Storms Ahead? 
03/26YOUR DAILY PHARMA SCOOP : Clovis Update, Novartis' MS Results, Vericel's SUMMIT .. 
03/23European advisory group thumbs down on Portola's betrixaban, appeal planned 
03/16Key events next week - healthcare 
03/13YOUR DAILY PHARMA SCOOP : Portola's New Interim Data, Lantheus Announces Promisi.. 
Chart PORTOLA PHARMACEUTICALS IN
Duration : Period :
Portola Pharmaceuticals In Technical Analysis Chart | PTLA | US7370101088 | 4-Traders
Technical analysis trends PORTOLA PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 53,5 $
Spread / Average Target 61%
EPS Revisions
Managers
NameTitle
William Lis Chief Executive Officer & Director
Hollings Chase Renton Chairman
Mardi C. Dier Chief Financial Officer & Executive Vice President
John T. Curnutte Executive Vice President-Research & Development
John H. Lawrence Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PORTOLA PHARMACEUTICALS INC-31.70%2 174
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873